Baxter’s Bioscience Business acquires biopharmaceutical company SuppreMol
6 March 2015 | By Baxter International Inc. / SuppreMol
Acquisition includes SuppreMol's early-stage pipeline of protein therapeutics for autoimmune and allergic diseases...
List view / Grid view
News
Combination cell-gene therapy for lung cancer to be tested in UK patients
6 March 2015 | By The Medical Research Council
A pioneering new combined cell-gene therapy to treat lung cancer will be tested in NHS patients this year, after receiving £2m of Biomedical Catalyst funding from the Medical Research Council...
ChemInteract consortium wins funding to develop chemical toxicity assessment tool
4 March 2015 | By Retrogenix
New technology aims to reduce animal testing and improve safety testing of chemicals...
‘Stem cell’ test could identify most aggressive breast cancers
4 March 2015 | By The Institute of Cancer Research
Testing breast cancer cells for how closely they resemble stem cells could identify women with the most aggressive disease, a new study suggests...
Manipulating cells’ shapes could treat breast cancer
4 March 2015 | By The Institute of Cancer Research
Changing the shape of breast cancer cells could make the disease more sensitive to treatments – even driving the body’s own inflammatory response against a tumour – a new study shows...
Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programs
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...
Northern Health Science Alliance welcomes funding to boost life and health sciences in the North of England
4 March 2015 | By The Northern Health Science Alliance
The NHSA’s ambitious project of establishing an internationally recognised life science and healthcare economy in the North of England has been given a vital boost following funding from HEFCE...
ORYX’ therapeutic vaccine MicOryx successfully completes Phase I/IIa trial to treat MSH-H colorectal cancer
4 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or…
Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC®, a prostate-specific antigen-targeting cancer immunotherapy
4 March 2015 | By Bristol-Myers Squibb Company
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales...
Data on Glutaminyl Cyclases (QCs) in its relation to Alzheimer’s Disease (AD) published in Acta Neuropathologica
3 March 2015 | By Probiodrug
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach...
MRC Technology launches respiratory ‘Call for Targets’
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
New breast cancer test links immune ‘hotspots’ to better survival
27 February 2015 | By The Institute of Cancer Research
Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of ‘hotspots’ where there has been a fierce immune reaction to a tumour...
Study of next-generation investigational HIV-1 maturation inhibitor shows positive results in preventing viral replication via different mechanism of action than current therapies
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1...
TxCell to present at ROTH Capital Partners investor conference in US
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
Launch of the anti-cancer agent / BRAF inhibitor “Zelboraf”
26 February 2015 | By Roche
Contribution to the treatment of melanoma by personalized healthcare...
